April 22, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, DC 20549
Attention: Todd Schiffman
Re: ContraVir Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended
File No. 333-229416
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), ContraVir Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m. (EDT) on Wednesday April 24, 2019, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at 212-634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
| Thank you, | |
|
| |
| CONTRAVIR PHARMACEUTICALS, INC. | |
|
| |
|
| |
| By: | /s/ Robert Foster |
|
|
|
| Name: | Robert Foster |
| Title: | Chief Executive Officer |
